Framework Nucleic Acids Enabled Pulmonary Artery Endothelial Cell Growth Inhibition by Targeting microRNA-152

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Nanomedicine

Background:

• Pulmonary artery vascular endothelial dysfunction is central to pulmonary vascular remodeling (PVR).
• MicroRNAs (miRNAs) are implicated in endothelial cell dysfunction and PVR.
• miRNA-152 is identified as a key player in hypoxia-induced human pulmonary artery endothelial cells (HPAECs) dysfunction.

Purpose of the Study:

• To investigate the role of miRNA-152 in HPAECs under hypoxic conditions.
• To develop and evaluate a novel nanomedicine for targeting miRNA-152 in HPAECs.
• To elucidate the therapeutic potential of targeting miRNA-152 against PVR.

Main Methods:

• Quantitative assessment of miRNA-152 expression in HPAECs under hypoxia.
• Design and synthesis of a DNA nanostructure (DNT-152) for miRNA-152 hybridization.
• In vitro evaluation of DNT-152 uptake, apoptosis induction, and growth inhibition in HPAECs.
• Mechanistic studies involving gene silencing and pathway analysis (AKT/mTOR).

Main Results:

• miRNA-152 was found to be overexpressed in HPAECs under hypoxia.
• DNT-152 demonstrated efficient cellular uptake and significantly inhibited HPAEC proliferation and induced apoptosis.
• DNT-152 effectively silenced miRNA-152, leading to Meox2 upregulation and inhibition of the AKT/mTOR pathway.

Conclusions:

• miRNA-152 is a critical mediator of endothelial cell dysfunction in the context of PVR.
• Framework nucleic acid nanostructures, like DNT-152, represent a promising therapeutic strategy for noncancerous diseases.
• Targeting miRNA-152 offers a potential new avenue for treating pulmonary vascular remodeling.